Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia. Diabetes technology & therapeutics Anderson, S. M., Buckingham, B. A., Breton, M. D., Robic, J. L., Barnett, C. L., Wakeman, C. A., Oliveri, M. C., Brown, S. A., Ly, T. T., Clinton, P. K., Hsu, L. J., Kingman, R. S., Norlander, L. M., Loebner, S. E., Reuschel-DiVirglio, S. n., Kovatchev, B. P. 2019

Abstract

Background: Typically, closed-loop control (CLC) studies excluded patients with significant hypoglycemia. We evaluated the effectiveness of hybrid CLC (HCLC) versus sensor-augmented pump (SAP) in reducing hypoglycemia in this high-risk population. Methods: Forty-four subjects with type 1 diabetes, 25 women, 37?±?2 years old, HbA1c 7.4%?±?0.2% (57?±?1.5?mmol/mol), diabetes duration 19?±?2 years, on insulin pump, were enrolled at the University of Virginia (N?=?33) and Stanford University (N?=?11). Eligibility: increased risk of hypoglycemia confirmed by 1 week of blinded continuous glucose monitor (CGM); randomized to 4 weeks of home use of either HCLC or SAP. Primary/secondary outcomes: risk for hypoglycemia measured by the low blood glucose index (LBGI)/CGM-based time in ranges. Results: Values reported: mean?±?standard deviation. From baseline to the final week of study: LBGI decreased more on HCLC (2.51?±?1.17 to 1.28?±?0.5) than on SAP (2.1?±?1.05 to 1.79?±?0.98), P?

View details for DOI 10.1089/dia.2019.0018

View details for PubMedID 31095423